RA0514

antibody from Oursmab

Targeting: MUC1 ADMCKD, ADMCKD1, CD227, MCD, MCKD, MCKD1, PEM, PUM

Western blot (Supportive data in Antibodypedia)

ELISA (Recommended by provider)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0514

Provider

Oursmab

Product name

Cantuzumab (Biosimilar Reference Antibody) (MUC1)

Antibody type

Monoclonal

Description

Cantuzumab mertansine is an investigational antibody-drug conjugate (ADC) that was developed for the treatment of solid tumors, particularly those expressing a specific tumor-associated antigen. It combines a humanized monoclonal antibody with a potent cytotoxic agent (DM1, a maytansine derivative) via a cleavable linker. Early clinical trials focused on cancers such as colorectal, pancreatic, and non-small cell lung cancer, but its development appears to have been discontinued due to limited efficacy or strategic portfolio decisions in later-phase studies.

Reactivity

Human

Isotype

IgG

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.

Western blot

Supportive validation

Submitted by

Oursmab (provider)

Main image

Experimental details

Cantuzumab (Biosimilar Reference Antibody) (MUC1)-RA0514-Oursmab determined by SDS-PAGE. The purity of the protein is greater than 98%.